KPV is a short peptide studied for inflammation signals in the gut. The evidence comes from cells and animals, with no published human trials identified. It is coming soon to Promise.
Coming soon
You are on the list. We will email you when KPV becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
KPV is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
KPV is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
In cell experiments, researchers have examined a carrier protein called PepT1 that brings this small peptide into intestinal cells, where inflammation signals are studied.
Published studies have examined cells and mouse models of gut inflammation. They have not established benefits or a safety profile for people receiving this peptide.
When visits open, a licensed provider will review your health history, medicines and existing digestive diagnoses before deciding whether a prescription is appropriate.
KPV is a peptide, a short chain of protein building blocks, studied for signals involved in gut inflammation. The evidence comes from cells and animals. No published human trial was identified in the sources reviewed.
KPV is coming soon to Promise — add me to the list.
The name stands for lysine, proline and valine, three amino acids, the building blocks of proteins. They form the tail of alpha-MSH, a hormone involved in pigment and inflammatory signaling. Pigment is what gives skin its color.
Researchers study this short fragment separately from the whole hormone. The interest is in inflammation-related activity without reproducing the parent's pigment signaling. That research idea does not establish a side-effect profile in people.
Our KPV peptide guide follows the molecule's wider research history. This page covers the standalone compound, how it differs from a blend, and what will happen when visits open.
The gut research asks how a small peptide gets inside a cell and what happens to inflammation signals there. A protein called PepT1 acts as a carrier, bringing small peptides into cells.
In Dalmasso and colleagues' cell and mouse study, published in 2008, PepT1 carried KPV into intestinal and immune cells grown in the lab. Researchers examined NF-kappaB, a protein that helps switch on genes involved in inflammation. The cells showed less activity in that signaling pathway and released fewer inflammatory messages.
Those experiments included cells derived from human tissue. That means human cells in a dish, rather than people receiving the compound. Entry into a cell and a change in a lab marker cannot tell us whether a person will feel better.
Dalmasso's group also examined chemically induced colitis, meaning inflammation of the colon, in mice. A separate 2008 study by Kannengiesser and colleagues examined both chemically induced inflammation and a model created by transferring immune cells. Both groups reported less inflammatory activity in the mouse models.
Delivery is another research question. In Laroui and colleagues' 2010 delivery study, researchers put the peptide inside nanoparticles, tiny carriers, and enclosed those in a gel for delivery by mouth. They tested that engineered preparation in cells and mice. Its findings belong to that preparation and cannot establish what a different formulation would do in a person.
A paper published online in August 2026 also examined mouse fat cells and mice fed a high-fat diet. It broadens the laboratory questions without supplying a human trial.
The KPV evidence guide separates the findings by study setting. None establishes a benefit for gut symptoms in people. KPV is not a replacement for care of a diagnosed digestive condition.
In its May 2026 KPV review, FDA found no clinical studies or human exposure data by any route. The agency said potential safety risks in humans are unknown. Missing human observations leave questions about harm unanswered.
As of October 6, 2026, KPV is not on the 503A bulks list, the FDA ingredient list for certain compounded prescriptions. On July 23, 2026, an advisory committee recommended adding it. No proposed or final rule has followed. A licensed provider may still prescribe — that decision is between you and your doctor.
The KPV FDA review timeline explains the recommendation. A compounded medication is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
KPV is a single peptide. KLOW, which Promise offers by prescription, combines it with BPC-157, TB-500 and GHK-Cu. The blend contains four different ingredients; it is not simply another name for this compound.
Studies of one ingredient do not test the whole mixture. Adding components does not establish an added benefit, and the separate cell and animal findings cannot establish the blend's safety.
BPC-157 is a different peptide in that blend and in this gut category. Sharing a category does not make the compounds interchangeable. The KLOW vs GLOW comparison explains where this fragment fits: Glow has the same other three ingredients, without it.
When visits open, the process will begin with the intake questionnaire written for this compound. It will cover your health history, medicines, allergies, digestive diagnoses and the reason for the request.
A licensed provider will review your answers and may ask for more information before deciding, or recommend care for the underlying digestive concern instead. The gut health and digestion hub explains that clinical context.
If prescribed, a licensed U.S. pharmacy will compound and dispense the medication. Your provider sets any protocol; Promise does not publish dosing. Follow-up check-ins from your care team will be part of the plan, with a clinician available to discuss questions or unwanted effects.
KPV is a peptide, a short chain of amino acids, the building blocks of proteins. Its name stands for lysine, proline and valine, the tail of a hormone called alpha-MSH. Researchers study it for inflammatory signaling in cells and animal models. Those findings have not established benefits or safety in people.
Yes. When visits open, KPV will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. The prescription decision will depend on your medical eligibility.
Starting a visit does not guarantee a prescription. When visits open, a licensed provider will review your health history, medicines and the reason for your request. They may ask for more information or decline if the compound is not appropriate. Joining the list now does not start a medical evaluation.
No. KPV is not FDA-approved, and no FDA-approved product contains it. The formulation Promise will offer is a compounded medication, which is not reviewed by the FDA for safety, effectiveness, or quality. A prescription will require a licensed provider to assess your history; it does not establish that the compound has demonstrated benefits or safety in people.
Not yet. KPV is coming soon to Promise — add me to the list on this page and we'll email you when visits open. Joining the list is a request for that notification. It does not begin a visit, reserve a prescription or establish that this compound will be appropriate for you.
KPV is one peptide; KLOW is a blend of four. KLOW contains KPV alongside BPC-157, TB-500 and GHK-Cu, and is offered by prescription through Promise. Research on an individual ingredient cannot establish the effects or safety of the mixture. More ingredients do not establish a greater benefit, and a provider will assess the full prescription being considered.
The direct evidence is from cells and animals. Researchers have examined how this peptide enters intestinal cells, inflammatory signaling and mouse models of colon inflammation. Delivery studies also use engineered preparations. No published human clinical trial was identified in the sources reviewed. It is not a replacement for care of a diagnosed digestive condition.
KPV sold online without a prescription may be labeled for laboratory use and come without a provider or pharmacy accountable for a patient prescription. When visits open at Promise, a licensed provider will decide whether it is appropriate, a licensed U.S. pharmacy will compound and dispense it if prescribed, and your care team will follow up.
Other Gut Health & Digestion options a provider may consider.
Gut Health & Digestion
A 15-amino-acid synthetic peptide studied for tissue-repair signaling, gut-lining support, and recovery.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.